COVID-19 UPDATE: We are open! Our team is working and offering consultations via phone, e-mail, and video conferencing.


Pradaxa, Xarelto Blood Thinners No Safer Than Warfarin: Study

PradaxaNewer-generation blood thinner drugs like Pradaxa and Xarelto are no safer than warfarin, the go-to anticoagulant medication that has been on the market for decades, according to the findings of a new study. In the study, published in the December issue of the Canadian Journal of Cardiology, researchers from the Southlake Regional Health Centre in Canada found that the safety profiles of warfarin, Pradaxa and Xarelto were nearly identical when it came to the risk of serious side effects like internal bleeding. If you took Pradaxa in the past, and you have since suffered a major bleeding event or another severe medication complication, consult our experienced Pradaxa lawyers at Bandas Law Firm today.


Pradaxa, manufactured by Boehringer Ingelheim, was approved by the U.S. Food and Drug Administration (FDA) in 2010, and was the first member of this new generation of blood thinners, followed by Bayer and Janssen Pharmaceuticals’ Xarelto anticoagulant in 2011. When the medications first arrived on the market, their manufacturing companies marketed the drugs as superior alternatives to warfarin, because they required less patient monitoring during treatment. However, new studies and internal documents have suggested that adequate blood monitoring among patients taking Pradaxa or Xarelto may have actually prevented many life-threatening bleeding problems.


Researchers involved in the blood thinner study examined data on 901 patients who underwent cardioversion and were prescribed warfarin or newer anticoagulant drugs like Pradaxa and Xarelto, focusing on the number of bleeding events, strokes and transient ischemic attacks affecting the patients. According to the findings of the study, there was “no significant difference” between the risk of bleeding from Pradaxa, Xarelto or warfarin, despite claims made by the manufacturers of the “Factor Xa” medications that newer-generation anticoagulant drugs are safer than warfarin, since they require less patient monitoring to avoid the risk of bleeding events.


As Pradaxa and other second-generation blood thinners become the more popular form of treatment for the prevention of strokes among patients with atrial fibrillation, serious concerns have been raised about the safety of these medications, as a large number of adverse event reports have been linked to uncontrollable bleeding problems from Pradaxa and Xarelto. If you believe you have been adversely affected by side effects of Pradaxa or another potentially dangerous pharmaceutical drug, contact our knowledgeable attorneys at Bandas Law Firm today for legal help. You may have grounds to file a Pradaxa lawsuit against Boehringer Ingelheim, in order to pursue financial compensation for your losses.